This invention relates generally to suture passer systems and methods for tissue suspension and tissue compression, and suspension lines, including embodiments with radially enlarged segments.
Disclosed herein are variable-thickness suspension line for suspending tissue. The suspension lines can include a suture having a first thickness dimension. In some embodiments, the suspension lines also include an elastomer surrounding a portion of the suture and defining a central segment of the suspension line having a second thickness dimension greater than the first thickness dimension. The suspension lines can also include at least one transition zone extending from the central segment of the suspension line to a lateral end of the suspension line, the transition zones having a thickness dimension that tapers from the second thickness dimension to the first thickness dimension.
In some embodiments, the suspension lines include a plurality of transition zones, each transition zone extending from the central segment of the suspension line to respective lateral ends of the suspension line. The elastomer can be overmolded onto the suture. The elastomer can be, for example silicone. The suture can be braided. The suspension line can also include a radiopaque marker operably attached to the suture. The radiopaque marker can be disposed on, for example, the central segment of the suspension line. The suspension line can extend axially along the entire length of the suspension line. The elastomer can be overmolded over a plurality of discontinuous segments of the suture. The central segment of the suspension line can include one or more knots for improving adhesion between the suture and the elastomer. The suspension line could have a rounded, and/or a rectangular cross-section. The central segment can be configured to move between a first axially unstretched configuration and a second axially stretched configuration. In some embodiments, the first thickness dimension can be less than about 0.020 inches. The second thickness dimension can be between about 0.080 inches and about 0.120 inches. An axial length of the central segment can be between about 2 cm and about 3 cm. An axial length of the transition zones can be less than about 1 cm.
Also disclosed herein is a variable-thickness suspension line for suspending tissue. The suspension line can include a tether having a first thickness dimension. The tether can have first and second lateral ends and a central segment. The suspension line can also have an elastomer surrounding and overmolded to the central segment of the tether and defining a central zone of the suspension line, the central zone having a second thickness dimension greater than the first thickness dimension.
In some embodiments, disclosed is a method for performing glossopexy. The method can include providing a variable-thickness suspension line comprising: a suture having a first thickness dimension, the suture extending axially along the suspension line; and an elastomer surrounding and overmolded to a segment of the suture, defining a central segment of the suspension line having a second thickness dimension greater than the first thickness dimension; and wherein areas of the suture not surrounded by the elastomer define lateral ends of the suspension line; passing the suspension line through the base of the tongue to form a loop in the suspension line; and tensioning the suspension line to suspend the tongue. The method can also include securing the suspension line to the mandible.
In some embodiments, as illustrated in
This application incorporates by reference in its entirety U.S. Pat. Pub. No. 2011/0245850 A1 to van der Burg et al. Embodiments of elements disclosed herein including bone anchors, suspension lines, and/or suture lock mechanisms can be used or modified for use with systems, apparatuses, and methods, including suture passers for tongue and other tissue compression as described in U.S. Pat. Pub. No. 2011/0245850 A1. The term “suture” as used herein, unless otherwise specified or limited, is intended to have its ordinary meaning and is also intended to include all structures, including any of the aforementioned or later-described examples, that can be passed through tissue using the devices described herein. One example of tissue that can be suspended or compressed is the genioglossus muscle of the tongue. Such a system could be useful in treating a wide range of conditions, including, for example, obstructive sleep apnea. Other non-limiting examples of tissues that can be suspended or compressed include using systems and methods as described herein include facial soft tissue such as in the forehead, brow, mid face, jowls, lateral face, lips, eyelids, nose, and neck to treat wrinkles or asymmetry; the breast and/or nipple-areola complex to treat ptosis; the bladder, such as the bladder neck to treat incontinence or a cystocele; the uterus or vagina to treat prolapse; or muscles, tendons, and/or ligaments to treat a partial or complete tear. The suture passer system could be used to ligate blood vessels such as arteries or veins that are not easily accessible without a surgical access procedure. Other non-limiting examples of anatomical structures that can be suspended other luminal structures such as a lymphatic, fallopian tube, bile duct, or ureter; or an organ such as, for example, the esophagus, stomach, small intestine, colon, rectum, bladder, uterus, vagina, eye, liver, lung, gallbladder, spleen, pancreas, or kidney. The suture passer can also be used to suspend other structures located within tissue, such as bone, as will be described further below.
In some embodiments, advantages of this design include providing a continuous first suture with a first, relatively smaller diameter, e.g., a #2 suture to ensure the strength of the loop and eliminating junctions that may reduce reliability. Also, the ability to securely “bulk up” a suspension line can be advantageous. Furthermore, the bulked-up configurations may be coated in silicone or another layer to further smooth transitions. The larger suture may also be glued or otherwise attached to the underlying suture. As illustrated in the suture coil 600 embodiment of
In some embodiments, the stretch element can provide limited compliance to allow for easier swallowing while still providing suspension for sleep apnea resolution. Some embodiments including limited compliance stretch elements are illustrated in
In some embodiments, as illustrated in
The cross-section of the suspension line 1100 along its length can be substantially round, oval, or other shapes in some embodiments. In some embodiments, there can be a transition region 1104 on either/both sides of the large diameter section 1102. The small diameter suture 1101 may or may not need to be continuous throughout the length of the suspension line 1100.
The surface of any of the disclosed suspension lines may be mechanically, chemically, or otherwise modified to improve adhesion with, for example, muscle cells and other tissues of the genioglossus. Mechanical modifications create improved adhesion by modifying the surface texture of the implant and may be achieved as part of the manufacturing process and may involve the removal of material from, or the addition of material to the surface of the implant. Chemical adhesion may be achieved through the incorporation of chemical (including biological) compounds into the surface or the bulk material or materials that makes up the implant in order to improve the affinity between cellular components and the implant. Compounds may include, but are not limited to proteins, peptides, antibodies, growth factors, or other molecules which create an affinity for cellular or tissue components.
In some embodiments, as illustrated in
In some embodiments, as illustrated in
Substantially vertical suture loop(s) placed at the midline of the tongue base may have additional advantageous as therapy for preventing an apnea event. First, by acting on the midline, the suture loop is less likely to affect the lateral walls of the pharynx. Second, if there is collapse of the tongue base against the posterior wall of the pharynx, the tissue may be “tented” at the midline, maintaining at least some pathway for air and avoiding complete obstruction of the pharynx. This is similar to the effect seen with a midline glossectomy.
Tissue 200 may be suspended by securing the free ends of suture loop(s) 105 to a structure such as a bone anchor (e.g., implanted in the mandible or hyoid bone) or other body structure outside the tissue 200. Other body structures in which the suture loop could be attached to include, for example, the hyoid bone or the soft palate. Alternatively, the free ends of suture may be tied in a knot or otherwise secured to suspend the tissue 200.
When tongue suspension is desired, the tongue could be accessed via the oral cavity. In some instances, embodiments of the tongue suspension system can be implanted through an antero-inferior access site of the mandible. Implantation of the system that avoids the transoral route may improve infection rates that occur with other tongue related devices and procedures.
A description of pharyngeal anatomy and a method for suspending the tongue will now be described.
The oropharynx 2 comprises structures from the soft palate 4 to the upper border of the epiglottis 7 and includes the hard palate 8, tongue 200, tonsils 10, palatoglossal arch 11, the posterior pharyngeal wall 12 and the mandible 302. The mandible typically has a bone thickness of about 5 mm to about 10 mm anteriorly with similar thicknesses laterally. An obstruction in the oropharynx 2 may result when the tongue 200 is displaced posteriorly during sleep as a consequence of reduced muscle activity during REM sleep. The displaced tongue 200 may push the soft palate 4 posteriorly and may seal off the nasopharynx 1 from the oropharynx 2. The tongue 200 may also contact the posterior pharyngeal wall 12, which causes further airway obstruction.
The hypopharynx 3 comprises the region from the upper border of the epiglottis 7 to the inferior border of the cricoid cartilage 14. The hypopharynx 3 further comprises the hyoid bone 15, a U-shaped, free floating bone that does not articulate with any other bone. The hyoid bone 15 is attached to surrounding structures by various muscles and connective tissues. The hyoid bone 15 lies inferior to the tongue 200 and superior to the thyroid cartilage 16. A thyrohyoid membrane 17 and a thyrohyoid muscle 18 attaches to the inferior border of the hyoid 15 and the superior border of the thyroid cartilage 16. The epiglottis 7 is infero-posterior to the hyoid bone 15 and attaches to the hyoid bone by a median hyoepiglottic ligament 19. The hyoid bone attaches anteriorly to the infero-posterior aspect of the mandible 302 by the geniohyoid muscle 20.
Methods of treating a condition of an airway will now be described. For example, the method can comprise creating a first pathway within the tongue 200 without passing through the mucosa, and creating a second pathway within the tongue 200. For example,
In
Steps as illustrated in
When suspending the tongue and advancing the genioglossus anteriorly, the precise placement and tensioning of an implant can avoid potentially increasing potential lateral collapse of the pharynx. Furthermore, tongue suspension using the methods and devices as disclosed herein can be advantageous as the procedure, in at least some embodiments, can be fully reversible by simply removing the suture(s).
In
As illustrated in
With reference to
Still referring to
In
In
As noted, systems and methods described herein can be used to suspend any biological structure such as tissue.
It is contemplated that various combinations or subcombinations of the specific features and aspects of the embodiments disclosed above may be made and still fall within one or more of the inventions. Further, the disclosure herein of any particular feature, aspect, method, property, characteristic, quality, attribute, element, or the like in connection with an embodiment can be used in all other embodiments set forth herein. Accordingly, it should be understood that various features and aspects of the disclosed embodiments can be combined with or substituted for one another in order to form varying modes of the disclosed inventions. Thus, it is intended that the scope of the present inventions herein disclosed should not be limited by the particular disclosed embodiments described above. Moreover, while the invention is susceptible to various modifications, and alternative forms, specific examples thereof have been shown in the drawings and are herein described in detail. It should be understood, however, that the invention is not to be limited to the particular forms or methods disclosed, but to the contrary, the invention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the various embodiments described and the appended claims. Any methods disclosed herein need not be performed in the order recited. The methods disclosed herein include certain actions taken by a practitioner; however, they can also include any third-party instruction of those actions, either expressly or by implication. For example, actions such as “passing a suspension line through the base of the tongue” include “instructing the passing of a suspension line through the base of the tongue.” The ranges disclosed herein also encompass any and all overlap, sub-ranges, and combinations thereof. Language such as “up to,” “at least,” “greater than,” “less than,” “between,” and the like includes the number recited. Numbers preceded by a term such as “approximately”, “about”, and “substantially” as used herein include the recited numbers, and also represent an amount close to the stated amount that still performs a desired function or achieves a desired result. For example, the terms “approximately”, “about”, and “substantially” may refer to an amount that is within less than 10% of, within less than 5% of, within less than 1% of, within less than 0.1% of, and within less than 0.01% of the stated amount.
This application claims priority under 35 U.S.C. §119(e) as a nonprovisional application of U.S. Prov. Pat. App. No. 61/698,457 filed on Sep. 7, 2012, which is hereby incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
2143910 | Didusch | Jan 1939 | A |
2167251 | Rogers | Jul 1939 | A |
3194239 | Sullivan | Jul 1965 | A |
3570497 | Lemole | Mar 1971 | A |
4034763 | Frazier | Jul 1977 | A |
4185626 | Jones et al. | Jan 1980 | A |
4372293 | Vijil-Rosales | Feb 1983 | A |
4441497 | Paudler | Apr 1984 | A |
4557264 | Hinsch | Dec 1985 | A |
4792336 | Hlavacek et al. | Dec 1988 | A |
4959069 | Brennan | Sep 1990 | A |
5250055 | Moore et al. | Oct 1993 | A |
5330488 | Goldrath | Jul 1994 | A |
5336231 | Adair | Aug 1994 | A |
5364407 | Poll | Nov 1994 | A |
5391174 | Weston | Feb 1995 | A |
5411523 | Goble | May 1995 | A |
5443482 | Stone et al. | Aug 1995 | A |
5534011 | Greene, Jr. et al. | Jul 1996 | A |
5620012 | Benderev | Apr 1997 | A |
5692530 | Bible et al. | Dec 1997 | A |
5722981 | Stevens | Mar 1998 | A |
5868789 | Huebner | Feb 1999 | A |
5895395 | Yeung | Apr 1999 | A |
5906624 | Wenstrom, Jr. | May 1999 | A |
5980559 | Bonutti | Nov 1999 | A |
5988171 | Sohn | Nov 1999 | A |
6096051 | Kortenbach et al. | Aug 2000 | A |
6258106 | Leonard | Jul 2001 | B1 |
6264677 | Simon et al. | Jul 2001 | B1 |
6273852 | Lehe et al. | Aug 2001 | B1 |
6554845 | Fleenor et al. | Apr 2003 | B1 |
6610080 | Morgan | Aug 2003 | B2 |
6638283 | Thal | Oct 2003 | B2 |
6638286 | Burbank et al. | Oct 2003 | B1 |
6660023 | McDevitt et al. | Dec 2003 | B2 |
6672316 | Weihrauch | Jan 2004 | B1 |
6746456 | Xiao | Jun 2004 | B2 |
6786913 | Sancoff et al. | Sep 2004 | B1 |
6984237 | Hatch et al. | Jan 2006 | B2 |
6991636 | Rose | Jan 2006 | B2 |
7081126 | McDevitt et al. | Jul 2006 | B2 |
7090672 | Underwood et al. | Aug 2006 | B2 |
7213599 | Conrad et al. | May 2007 | B2 |
7232448 | Battles | Jun 2007 | B2 |
7237554 | Conrad et al. | Jul 2007 | B2 |
7306613 | Kawashima et al. | Dec 2007 | B2 |
7337781 | Vassallo | Mar 2008 | B2 |
7367340 | Nelson et al. | May 2008 | B2 |
7401611 | Conrad et al. | Jul 2008 | B2 |
7625386 | Abe et al. | Dec 2009 | B2 |
7673635 | Conrad et al. | Mar 2010 | B2 |
7674276 | Stone et al. | Mar 2010 | B2 |
7703460 | Conrad et al. | Apr 2010 | B2 |
7867251 | Colleran et al. | Jan 2011 | B2 |
7892256 | Grafton | Feb 2011 | B2 |
7918868 | Marshall et al. | Apr 2011 | B2 |
8096303 | Dineen et al. | Jan 2012 | B2 |
8167787 | Gillis | May 2012 | B2 |
8177795 | Niese et al. | May 2012 | B2 |
8236027 | Wu | Aug 2012 | B2 |
8460322 | van der Burg et al. | Jun 2013 | B2 |
20030149447 | Morency et al. | Aug 2003 | A1 |
20040134491 | Pflueger et al. | Jul 2004 | A1 |
20050119696 | Walters et al. | Jun 2005 | A1 |
20050126563 | van der Burg et al. | Jun 2005 | A1 |
20050149122 | McDevitt et al. | Jul 2005 | A1 |
20050192631 | Grafton | Sep 2005 | A1 |
20050288690 | Bourque et al. | Dec 2005 | A1 |
20060070626 | Frazier et al. | Apr 2006 | A1 |
20060106423 | Weisel et al. | May 2006 | A1 |
20060150986 | Roue et al. | Jul 2006 | A1 |
20060201519 | Frazier et al. | Sep 2006 | A1 |
20060207606 | Roue et al. | Sep 2006 | A1 |
20060207607 | Hirotsuka et al. | Sep 2006 | A1 |
20060207608 | Hirotsuka et al. | Sep 2006 | A1 |
20060207612 | Jackson et al. | Sep 2006 | A1 |
20060271060 | Gordon | Nov 2006 | A1 |
20060276817 | Vassallo et al. | Dec 2006 | A1 |
20060282081 | Fanton et al. | Dec 2006 | A1 |
20060282082 | Fanton et al. | Dec 2006 | A1 |
20060282083 | Fanton et al. | Dec 2006 | A1 |
20060282088 | Ryan | Dec 2006 | A1 |
20070144539 | van der Burg et al. | Jun 2007 | A1 |
20070149986 | Morris et al. | Jun 2007 | A1 |
20070149987 | Wellman et al. | Jun 2007 | A1 |
20070179509 | Nagata et al. | Aug 2007 | A1 |
20070225763 | Zwolinski et al. | Sep 2007 | A1 |
20070261701 | Sanders | Nov 2007 | A1 |
20070288057 | Kuhnel | Dec 2007 | A1 |
20080023012 | Dineen et al. | Jan 2008 | A1 |
20080027480 | van der Burg et al. | Jan 2008 | A1 |
20080027560 | Jackson et al. | Jan 2008 | A1 |
20080035160 | Woodson et al. | Feb 2008 | A1 |
20080053461 | Hirotsuka et al. | Mar 2008 | A1 |
20080058584 | Hirotsuka et al. | Mar 2008 | A1 |
20080066767 | Paraschac et al. | Mar 2008 | A1 |
20080066769 | Dineen et al. | Mar 2008 | A1 |
20080077162 | Domingo | Mar 2008 | A1 |
20080082113 | Bishop | Apr 2008 | A1 |
20080091219 | Marshall et al. | Apr 2008 | A1 |
20080103506 | Volpi et al. | May 2008 | A1 |
20080154286 | Abbott et al. | Jun 2008 | A1 |
20080208265 | Frazier et al. | Aug 2008 | A1 |
20080275469 | Fanton et al. | Nov 2008 | A1 |
20090014012 | Sanders | Jan 2009 | A1 |
20090018554 | Thorne et al. | Jan 2009 | A1 |
20090069824 | Chu | Mar 2009 | A1 |
20090099598 | McDevitt et al. | Apr 2009 | A1 |
20090105753 | Greenhalgh et al. | Apr 2009 | A1 |
20090125043 | Dehnad | May 2009 | A1 |
20090228041 | Domingo | Sep 2009 | A1 |
20090318938 | Hathaway et al. | Dec 2009 | A1 |
20090318958 | Ochiai | Dec 2009 | A1 |
20100004683 | Hoof et al. | Jan 2010 | A1 |
20100106169 | Niese et al. | Apr 2010 | A1 |
20100114123 | Nason | May 2010 | A1 |
20100132719 | Jacobs et al. | Jun 2010 | A1 |
20100160962 | Dreyfuss et al. | Jun 2010 | A1 |
20100262184 | Dreyfuss | Oct 2010 | A1 |
20110004242 | Stchur | Jan 2011 | A1 |
20110308529 | Gillis et al. | Dec 2011 | A1 |
20120017919 | Gillis et al. | Jan 2012 | A1 |
20120132214 | Gillis et al. | May 2012 | A1 |
20130345724 | van der Burg et al. | Dec 2013 | A1 |
20140074158 | Feezor et al. | Mar 2014 | A1 |
Number | Date | Country |
---|---|---|
WO 2011151745 | Dec 2011 | WO |
WO 2011151745 | Dec 2011 | WO |
Entry |
---|
Frank G. DeLuca, M.D., and Conrad W. Wesselhoeft, M.D., Surgically Treatable Causes of Neonatal Respiratory Distress, 5 Clinics in Perinatology 377 (1978). |
Beverly Douglas, M.D., The Treatment of Micrognathia Associated with Obstruction by a Plastic Procedure, in 1 Plastic & Reconstructive Surgery 300, (Warren B. Davis ed., The Williams & Wilkins Co. 1946). |
International Search Report dated Jun. 10, 2011 in International Patent Application No. PCT/US2011/030829. |
H. Faye-Lund, G. Djupesland, & T. Lyberg, Glossopexia—Evaluation of a New Surgical Method for Treating Obstructive Sleep Apnea Syndrome, 492 Acta Oto-Laryngologica 46 (1990). |
Abraham Lapidot, M.D. and Nahum Ben-Hur, M.D., Fastening the Base of the Tongue Forward to the Hyoid for Relief of Respiratory Distress in Pierre Robin Syndrome, 56 Plastic & Reconstructive Surgery 89 (1975). |
Stephen R. Lewis, M.D., John B. Lynch, M.D., & Truman G. Blocker, Jr., M.D., Fascial Slings for Tongue Stabilization in the Pierre Robin Syndrome, 42 Plastic & Reconstructive Surgery 237 (1968). |
Chris T. Oeconomopoulos, M.D., The Value of Glossopexy in Pierre-Robin Syndrome, 262 NEJM 1267 (1960). |
Peter Randall, M.D., The Robin Anomalad: Micrognathia and Glossoptosis with Airway Obstruction, Reconstructive Plastic Surgery 2241 (2nd ed., W.B. Saunders Co. 1977). |
Robert W. Riley, DDS, MD, Nelson B. Powell, MD and Christian Guilleminault, MD, Obstructive Sleep Apnea and the Hyoid: A Revised Surgical Procedure, 111 Otolaryngol Head Neck Surgery 717 (1994). |
M.R. Wexler, H. Kaplan, K. Abu-Dalu, & M. Rousso, A Dynamic Fixation of the Base of the Tongue to the Mandible Using De-epithelized Tongue Flap in the Pierre Robin Syndrome, 4 Chirurgia Plastica 297 (1979). |
Robert M. Woolf, M.D., Nicholas Georgiade, M.D., and Kenneth L. Pickrell, M.D., Micrognathia and Associated Cleft Palate, 26 Plastic & Reconstructive Surgery 199 (1960). |
International Search Report dated Dec. 19, 2013 in International Patent Application No. PCT/US2013/058547. |
Number | Date | Country | |
---|---|---|---|
20140074158 A1 | Mar 2014 | US |
Number | Date | Country | |
---|---|---|---|
61698457 | Sep 2012 | US |